Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2009

View Archived Issues

Dasatinib q.d. shows similar clinical activity but less severe adverse events than b.i.d.

Korean FDA approves KLS' phase IIa clinical trial of TissueGene-C in DJD

Novel Toll-like receptor 7 agonists developed by Pfizer

Yamada Apiculture Center presents novel antidepressant compound

Janssen Pharmaceutica describes novel pyrrolopyrimidines for cancer treatment

New pyridine analogues claimed by AstraZeneca for treating thrombotic disorders

Triazole derivative SCD inhibitors disclosed by GlaxoSmithKline

ArQule expands clinical development program for ARQ-197 to include HCC

European Commission and FDA approve intravenous formulation of temozolomide

AnGes and FDA reach agreement on design for phase III clinical trial of Collategene

BMS, Nissan Chemical and Teijin sign global collaboration agreement for NTC-801

Torcetrapib differentially regulates high-density lipoprotein-2 and -3 in dyslipidemia

ThromboGenics completes patient enrollment for phase II microplasmin trial

Peplin reports phase IIb actinic keratosis trial results for PEP-005

Preliminary phase II study results for SEP-225441 do not meet endpoint in GAD

Forest and Almirall update clinical development program for aclidinium bromide in COPD

FDA to apply December 2008 guidance when reviewing Takeda's NDA for alogliptin

Entorhinal BDNF gene delivery neuroprotective in Alzheimer's disease models

Anacor reports encouraging results from phase I AN-2898 safety trial

Apeiron Biologics describes recombinant ACE2 synthesis, preclinical activity

Orion withdraws E.U. application to extend indication of Stalevo

Pharmos modifies phase IIb dextofisopam trial size

Acrux completes enrollment in phase III Axiron trial in hypogonadal men

Phase II psoriasis study of Arana's ART-621 successfully completed

Opko terminates phase III bevasiranib trial for wet AMD

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...